

**LIVE WEBINAR**

Thursday, November 12, 2020 • 12:00 PM ET/9:00 AM PT

[Register now](#)

# KRAS G12C Mutation: An Emerging Actionable Biomarker for NSCLC

Presented by:

**Yuri Fesko, MD**Director of Hematopathology,  
Quest Diagnostics  
Secaucus, New Jersey

As a leading oncologist, Dr Fesko plays a key role in helping Quest advance the field of precision medicine and give new hope to people with cancer. Prior to joining Quest in 2017, Dr Fesko was director of medical oncology at the Duke Cancer Institute in Raleigh, North Carolina, where he was responsible for the oncology service line and development of inpatient oncology, multiple network sites, and infusion centers. He also was responsible for strategies, including the determination of appropriate clinical trials for population and resource utilization. Dr Fesko received his bachelor's degree and medical degree from Case Western Reserve University School of Medicine. He is certified by the American Board of Internal Medicine in hematology and medical oncology.

**Kari Hooper, MD**Pathologist, AmeriPath®/  
Quest Diagnostics  
Department Chair,  
Integrus Baptist Medical Center  
Oklahoma City, Oklahoma

Dr Hooper joined Quest 5 years ago and quickly rose to become the Director of Hematopathology, Oklahoma City Lab. She leads a team to implement the molecular reflex program and actively participates on several molecular testing committees. In addition to her responsibilities at Quest, she is also the pathology NMM, ...department chair at Integra Baptist Medical Center in Oklahoma City, a 500-bed hospital system. Dr Hooper completed her anatomic and clinical pathology residency at University of Arkansas for Medical Sciences, followed by fellowships in hematopathology and cytopathology at University of Alabama at Birmingham. She is a College of American Pathologists (CAP) state delegate and an active member of the CAP political action committee.

To register for this live webinar, please visit: [QuestDiagnostics.com/EventRegistration](https://QuestDiagnostics.com/EventRegistration)

Please note: Advance registration is required for participation.

## Program objectives

At the conclusion of this program, participants will be able to:

- Discuss the evolution of biomarkers in NSCLC
- Describe KRAS and KRAS G12C prevalence information
- Explain diagnostic strategies and options for KRAS G12C testing

For more information, contact your Quest Diagnostics representative or email [EducationalEvents@QuestDiagnostics.com](mailto:EducationalEvents@QuestDiagnostics.com).

Visit [QuestDiagnostics.com/Education](https://QuestDiagnostics.com/Education) to view on demand webinars.

**Contact us:**

Quest Diagnostics • 500 Plaza Drive • Secaucus, New Jersey 07094 • Attention: Medical Marketing

Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics.  
©2020 Quest Diagnostics Incorporated. All rights reserved. MI9624 9/2020

This communication is intended for healthcare professionals in the USA.

[Unsubscribe from updates.](#)